- Investing.com
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the United States. The company operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, federal, and corporate management services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Regulatory Tightrope | Centene navigates complex healthcare policies, balancing growth opportunities with potential threats from ACA subsidy changes and Medicaid reforms |
Financial Resilience | Conservative guidance and undervalued status suggest potential for positive surprises, with analysts projecting EPS growth to $10 by 2027 |
Unveiling Growth Avenues | Explore Centene's strategies for margin expansion in Medicaid and Medicare, capitalizing on dual-eligible markets and emerging ICHRA opportunities |
Market Valuation | Analyst price targets range from $65 to $93, reflecting diverse views on Centene's ability to overcome challenges and leverage its strong market position |
Metrics to compare | CNC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNCPeersSector | |
---|---|---|---|---|
P/E Ratio | 4.2x | 20.4x | −0.5x | |
PEG Ratio | 0.13 | −0.21 | 0.00 | |
Price/Book | 0.5x | 1.4x | 2.6x | |
Price / LTM Sales | 0.1x | 0.9x | 3.2x | |
Upside (Analyst Target) | 53.0% | 32.0% | 41.9% | |
Fair Value Upside | Unlock | 15.6% | 4.3% | Unlock |